Top 30 Healthcare & BioTech Venture Capital 2026

This report forms part of the Capital Ranking Venture Capital series, which evaluates specialist venture investors, startup-financing platforms, and private-market institutions across major strategy and company-development categories.

Healthcare and biotech venture capital firms finance companies that translate scientific discovery, medical technology, clinical insight, and new care models into durable businesses. Their work differs materially from general technology investing. A therapeutic company may require years of preclinical and clinical development before commercial revenue is possible, while a medical-device or healthtech company must often navigate regulation, reimbursement, clinical adoption, data governance, and complex provider or payer procurement.

The category consequently demands more than access to capital. Specialist investors must evaluate biological mechanisms, modalities, intellectual property, translational evidence, clinical endpoints, regulatory pathways, manufacturing, reimbursement, healthcare workflows, and the sequencing of successive financing rounds. Many of the most influential firms also create companies, recruit executives, license academic discoveries, assemble development plans, and build syndicates before a conventional startup is fully formed.

This ranking identifies independent venture firms and healthcare investment platforms with sustained relevance across biotechnology, biopharma, therapeutics, diagnostics, medical devices, life-sciences tools, healthcare technology, and care delivery. It evaluates specialist authority, scientific and clinical depth, company-building capability, institutional continuity, international reach, and current market activity rather than ranking firms by a single fund’s return, one portfolio-company outcome, announced assets under management, or the number of investments completed.

Market Overview

Healthcare venture capital spans several markets with different risk structures. In therapeutics, investors underwrite target biology, modality selection, preclinical evidence, clinical differentiation, development timelines, and the probability that a program can reach patients. In diagnostics and life-sciences tools, they must assess analytical performance, clinical utility, laboratory economics, research workflows, and adoption by pharmaceutical or healthcare customers.

Medtech investors face another set of questions: product design, engineering reliability, regulatory classification, clinical evidence, physician behavior, hospital purchasing, reimbursement, and manufacturing scale. Healthtech investors evaluate software and data, but also need to understand healthcare integration, buyer incentives, patient safety, privacy, long enterprise sales cycles, and whether a product produces measurable clinical or economic value.

These differences make specialist networks unusually important. The strongest healthcare investors connect scientific founders with experienced executives, clinical investigators, regulators, pharmaceutical partners, health systems, payers, later-stage investors, and public markets. They also help companies determine which evidence must be generated before the next financing or strategic transaction becomes possible.

Geography shapes the market as well. Boston, San Francisco, New York, San Diego, and other US hubs retain exceptional depth in private capital and life-sciences talent. Europe contributes major academic and pharmaceutical ecosystems across the United Kingdom, France, Switzerland, Germany, the Netherlands, Belgium, Spain, and the Nordic countries. Australia, Canada, Singapore, and other research-intensive markets add scientific, clinical, and commercialization capabilities that increasingly connect into global syndicates.

Industry Trend — 2026

The 2026 healthcare venture market shows recovery, but not a return to indiscriminate financing. HSBC Innovation Banking’s 2026 Mid-Year Healthcare Venture Report described an upswing that began in late 2025 and strengthened during the first half of 2026. Investment was tracking ahead of 2025 across biopharma, diagnostics and tools, and medical devices, supported by improving M&A and a partially open IPO market. HSBC forecast $65–70 billion of full-year healthcare venture investment, while cautioning that a small number of $400 million-plus rounds could materially change the total.

Selectivity remains central. Silicon Valley Bank’s H1 2026 Healthcare Investments and Exits report found a 7% year-over-year decline in deal count as investors wrote fewer checks and demanded stronger fundamentals. The pullback was not uniform: healthtech and devices proved more stable, biopharma investment declined from recent levels, and diagnostics and tools remained under pressure.

Artificial intelligence is now embedded across the sector rather than confined to a separate niche. SVB estimated that healthcare-AI companies in the United States and Europe received nearly $18 billion in 2025, representing 46% of healthcare investment under its methodology. The opportunity includes drug discovery, clinical development, diagnostics, medical imaging, administrative workflows, provider operations, and patient engagement, but the diligence burden is rising as investors distinguish durable clinical or data advantages from features that general-purpose models can reproduce.

Digital health has regained momentum. Rock Health’s H1 2026 market review recorded $7.4 billion across 244 US digital-health deals, compared with $6.4 billion across 245 deals a year earlier. Yet 20 mega-rounds accounted for 45% of invested capital. The figures illustrate the wider market pattern: aggregate capital is recovering, but it is concentrated in companies able to demonstrate scale, differentiated data or workflows, credible clinical value, and durable customer relationships.

Biopharma is experiencing a related shift toward disciplined early-stage risk. HSBC reported stronger first-financing activity and renewed interest in preclinical companies, while mega-rounds continued to represent approximately 58–60% of sector funding over the preceding three years. China-originated clinical assets, AI-enabled discovery, radiopharmaceuticals, obesity and cardiometabolic medicine, autoimmune disease, neuroscience, and new therapeutic modalities are reshaping company-formation strategies. Investors must therefore combine scientific conviction with careful licensing, development, geopolitical, manufacturing, and capital-planning judgment.

2026 market indicator	Current evidence	Implication for healthcare and biotech investors
Full-year healthcare VC outlook	HSBC forecasts $65–70 billion of 2026 investment	The market is recovering, but ultra-large rounds can materially distort headline totals
Healthcare deal count	SVB reports a 7% year-over-year decline	Investors are concentrating capital in fewer companies with stronger fundamentals and milestone plans
Healthcare AI	Nearly $18 billion of US and European investment in 2025, representing 46% of healthcare investment under SVB’s methodology	AI is becoming part of scientific and operational diligence across every healthcare subsector
US digital health	$7.4 billion across 244 deals in H1 2026	Funding has improved, but enterprise adoption, clinical value, and defensible workflows remain decisive
Digital-health concentration	Twenty mega-rounds represented 45% of H1 2026 capital	Aggregate growth does not imply broadly easier financing for early-stage companies
Healthtech first financings	$1.7 billion across 141 deals in H1 2026 under HSBC’s broader methodology	Early-stage formation is active where founders can demonstrate domain expertise and credible routes to adoption
Biopharma concentration	Mega-rounds represented approximately 58–60% of funding over the preceding three years	Specialist investors need reserves, syndicate depth, and disciplined clinical milestone planning
Medical-device financing	Twenty-four $50 million-plus financings in H1 2026	Device companies remain financeable when regulatory, clinical, and commercialization pathways are credible

The cited datasets use different geographic boundaries and sector taxonomies. They should be read as complementary indicators rather than added together as one market total.

Methodology — Core Eligibility Criteria

Firms considered for this ranking were required to satisfy the following core conditions:

• Operate as an independent venture capital firm or maintain a clearly identifiable and institutionally meaningful healthcare, biotechnology, life-sciences, medtech, diagnostics, or healthtech investment franchise
• Demonstrate repeated participation in company creation, seed and venture financing, growth financing, or the commercialization of healthcare innovation
• Maintain active portfolio involvement, a current investment organization, and visible market presence during the 2026 evaluation period
• Possess scientific, clinical, regulatory, healthcare-operating, engineering, data, or sector-specific investment expertise
• Show sufficient specialist authority, institutional substance, founder access, company-building capability, or ecosystem influence to justify inclusion
• Support companies through practical capabilities such as management recruitment, translational planning, clinical development, regulatory strategy, reimbursement, provider access, commercialization, syndicate formation, or subsequent financing

Corporate venture-capital arms, pharmaceutical-company investment divisions, hospital-owned funds, bank-owned platforms, direct government investment agencies, accelerator-only organizations, broad generalist investors without a sustained healthcare franchise, inactive firms, winding-down organizations, and acquired brands without meaningful independent identity were excluded or de-emphasized.

A firm did not need to invest exclusively at the earliest venture stages. Multi-stage healthcare investment managers remained eligible where private-company formation and venture financing represented a sustained and institutionally important part of the platform. Firms spanning private and public healthcare markets were evaluated on the substance of their venture franchise rather than their public-market activity alone.

Methodology — Ranking Factors

The selected firms were evaluated using a combination of qualitative and structural factors:

• Strength, clarity, and continuity of the healthcare, biotechnology, or life-sciences investment identity
• Scientific, clinical, regulatory, reimbursement, engineering, healthcare-data, and operating expertise
• Record of company formation, early-stage investing, venture leadership, growth financing, and specialist syndication
• Ability to assess target biology, therapeutic modality, translational evidence, clinical endpoints, medical-device pathways, diagnostics, and healthcare workflows
• Capacity to recruit management, shape development strategy, secure intellectual property, build boards, and organize follow-on financing
• Sector depth across therapeutics, biotechnology platforms, diagnostics, life-sciences tools, medtech, healthcare software, services, data, and care delivery
• Scale and structure of capital available for long development cycles, milestone-based financing, and portfolio reserves
• Access to universities, research institutes, clinical investigators, pharmaceutical companies, health systems, payers, strategic partners, and public markets
• Geographic reach and ability to connect local scientific ecosystems with international capital, development, and commercialization pathways
• Current investment activity, organizational continuity, portfolio development, and visible institutional relevance during the 2026 evaluation period
• Contribution to distinctive specialist models, including venture creation, academic spinout formation, clinical-stage growth investment, and healthcare-technology commercialization
• Credibility as a lead investor or specialist co-investor capable of providing institutional signaling to founders, later investors, and strategic partners

The assessment universe comprised approximately 130 healthcare venture firms, biotech and life-sciences specialists, medtech investors, healthtech funds, scientific venture creators, and multi-stage healthcare investment platforms. Thirty firms were selected.

Tier classifications reflect relative institutional positioning within the healthcare and biotech venture-capital ecosystem. They do not constitute an investment recommendation, fund-performance ranking, fundraising endorsement, scientific-validation conclusion, clinical opinion, regulatory assessment, or prediction of portfolio-company outcomes.

Company Profiles and Further Reference

Firm names appearing in this ranking are linked to their corresponding profiles in The Economy Wiki for companies, where available. These profiles provide additional background on each organization, including its principal activities, sector focus, market positioning, leadership, corporate information, and related rankings and analysis across The Economy Network.

The Economy Wiki profiles are maintained as editorial reference pages and may be updated as new public information becomes available.

---

Tier I — Leading Healthcare & BioTech Venture Capital Platforms

ARCH Venture Partners

• Headquarters: Chicago / San Francisco / Seattle, United States
• Founded: 1986

ARCH Venture Partners is one of the defining institutions in science-led company formation. It frequently invests close to the origin of an idea, working with academic researchers, scientific founders, and experienced operators to create companies around biotechnology, therapeutics, diagnostics, research tools, and other technically ambitious innovations.

Its role often begins before conventional venture metrics are available. ARCH helps establish intellectual-property positions, recruit executives, define development strategies, assemble boards and syndicates, and finance the experiments required to determine whether a scientific concept can become an institutional company.

The firm’s breadth across life sciences and adjacent frontier technologies strengthens its ability to identify discoveries that do not fit established categories. Its long operating history also provides perspective across financing cycles in which scientific enthusiasm, public-market conditions, and capital availability have changed sharply.

ARCH fits Tier I because its scientific access, company-creation record, institutional continuity, and willingness to underwrite foundational technical risk make it a principal benchmark for healthcare and biotech venture capital.

Flagship Pioneering

• Headquarters: Cambridge, United States
• Founded: 2000

Flagship Pioneering combines investment management with a systematic venture-creation model. Its internal teams explore scientific hypotheses, develop platform concepts, form companies, recruit leadership, and finance development across biotechnology, therapeutics, health, life sciences, agriculture, and sustainability.

This structure is particularly relevant in biotechnology, where a promising discovery may need extensive validation and organizational design before it can operate as a standalone company. Flagship’s model allows scientific exploration, intellectual property, platform architecture, management recruitment, and capital formation to develop together.

The platform is also well positioned as computational biology, programmable medicine, synthetic biology, and AI-enabled discovery reshape the boundaries between scientific disciplines. It can organize companies around new technical systems rather than wait for a conventional financing opportunity to emerge.

Flagship fits Tier I because its scale, scientific ambition, venture-origination capability, and distinctive institutional model have influenced how modern biotech companies are conceived and built.

Third Rock Ventures

• Headquarters: Boston, United States
• Founded: 2007

Third Rock Ventures is a dedicated life-sciences firm focused on creating and financing companies that address important medical needs. It works closely with scientific founders, entrepreneurs, and operating executives to convert research opportunities into biotechnology companies with coherent scientific, clinical, organizational, and financing plans.

The firm’s company-building approach is central to its authority. Early biotechnology ventures must make decisions about target biology, modality, indication, translational evidence, development sequence, intellectual property, and leadership before the market can value them through conventional measures.

Third Rock benefits from deep participation in the Boston-Cambridge ecosystem while investing through wider scientific and industry networks. Its ability to recruit specialized teams and organize companies around emerging areas of medicine gives it influence beyond passive capital provision.

Third Rock fits Tier I because dedicated biotech company creation remains the organizing principle of the firm. Its scientific discipline, operating involvement, and institutional reputation make it one of the category’s clearest reference platforms.

OrbiMed

• Headquarters: New York / San Francisco / Shanghai, United States / global platform
• Founded: 1989

OrbiMed is one of the largest specialist healthcare investment platforms globally. It invests across biotechnology, pharmaceuticals, medical devices, diagnostics, healthcare services, and technology through strategies that include venture capital, growth equity, public equities, credit, royalties, and other forms of healthcare finance.

Its multi-strategy structure gives private companies access to a broad view of scientific development, pharmaceutical markets, clinical milestones, strategic transactions, and public-market conditions. That perspective is valuable where financing requirements change substantially as a company moves from early discovery through clinical development and commercialization.

OrbiMed’s international presence also reflects the globalization of healthcare innovation. Scientific assets, clinical programs, pharmaceutical partners, and capital increasingly move between North America, Europe, and Asia, requiring investors with cross-border networks and regulatory awareness.

OrbiMed fits Tier I because the scale, continuity, specialist depth, global reach, and venture relevance of its healthcare platform make it an institutional anchor, even though its activities extend well beyond venture capital alone.

Versant Ventures

• Headquarters: San Francisco / Vancouver / Basel, United States / Canada / Switzerland
• Founded: 1999

Versant Ventures is a healthcare investment firm with a strong record in biotechnology company creation and early-stage life-sciences investing. Its presence across North America and Europe connects scientific founders with major research, pharmaceutical, clinical, and financing ecosystems.

The firm frequently supports opportunities from initial concept through company formation and development. Its operating model includes discovery and company-building capabilities that help structure intellectual property, validate scientific programs, recruit management, and organize institutional syndicates.

This cross-border architecture is particularly valuable for European and Canadian discoveries that require access to US capital and commercialization networks, and for US companies seeking international science, development, or pharmaceutical relationships.

Versant fits Tier I because its specialist identity, company-formation capabilities, international platform, and sustained role in therapeutics development place it among the leading healthcare and biotech venture institutions.

---

Tier II — Established Healthcare & BioTech Venture Capital Firms

(Alphabetical order)

5AM Ventures

• Headquarters: San Francisco / Boston, United States
• Founded: 2002

5AM Ventures funds and builds life-sciences companies, with a principal focus on early-stage therapeutics, drug-delivery technologies, and life-sciences instruments. Its venture strategy typically concentrates on private companies at Series A and related formation stages.

The firm’s 4:59 Initiative provides an internal mechanism for working with academics and entrepreneurs before a conventional company is fully established. It supports experimental validation, company design, and the proof required for larger institutional financing.

5AM fits Tier II because its early-stage focus, company-building infrastructure, specialist team, and long continuity give it a strong position in biotech venture formation without the broader institutional reach of the Tier I platforms.

Atlas Venture

• Headquarters: Cambridge, United States
• Founded: 1980

Atlas Venture is a long-established life-sciences firm focused on creating and investing in biotechnology companies. Its Cambridge base provides close access to universities, research institutes, pharmaceutical companies, scientific founders, and experienced biotech executives.

The firm works at the formation stage, where investors must convert a scientific concept into a focused company with appropriate intellectual property, leadership, indication strategy, experimental plans, and financing architecture. Its history across multiple biotech cycles strengthens its judgment about scientific promise and capital requirements.

Atlas fits Tier II because company creation, ecosystem access, specialist longevity, and continued relevance remain central to its institutional identity.

Deerfield Management

• Headquarters: New York, United States
• Founded: 1994

Deerfield Management is a healthcare-focused investment firm active across private and public markets. Its platform spans biotechnology, pharmaceuticals, medical technology, healthcare services, and related innovation, with the capacity to provide several forms of capital across a company’s lifecycle.

The firm combines scientific and clinical expertise with capital-markets and operating perspectives. This is relevant to venture-backed companies whose development plans may require early equity, later private rounds, structured financing, institutional partnerships, and eventual public-market access.

Deerfield fits Tier II because it is broader than a conventional venture fund, yet healthcare specialization and private-company financing remain institutionally significant. Its scale and lifecycle perspective give it a major role in healthcare innovation finance.

Forbion

• Headquarters: Naarden / Amsterdam / Munich / Boston / Singapore, Netherlands / Germany / United States / Singapore
• Founded: 2006

Forbion is a specialist life-sciences investment firm with deep roots in European biotechnology and an increasingly international platform. It invests across therapeutics and related medical innovation from company formation and venture stages through later private-market development.

The firm is particularly relevant to companies that need to connect European scientific assets with US capital, pharmaceutical relationships, clinical-development expertise, and global commercialization pathways. Its team and office network support cross-border company building rather than purely regional investing.

Forbion fits Tier II because its specialist authority, institutional scale, European leadership, and active international expansion make it one of the strongest life-sciences venture platforms outside the United States.

Foresite Capital

• Headquarters: San Francisco, United States
• Founded: 2011

Foresite Capital is a multi-stage healthcare and life-sciences investor operating at the intersection of biology, data, and technology. It backs therapeutics, diagnostics, genomics, life-sciences tools, healthcare data, and companies applying computation to biomedical development.

Its model is relevant as drug discovery and healthcare increasingly depend on large biological datasets, machine learning, multimodal evidence, and technical infrastructure. Foresite also supports company formation through an internal venture-building capability.

Foresite fits Tier II because its technical team, multi-stage capital, company-creation resources, and coherent biology-and-data thesis give it strong category relevance in both traditional life sciences and computational healthcare.

Frazier Life Sciences

• Headquarters: Seattle / Palo Alto / San Diego / Boston, United States
• Founded: 1991

Frazier Life Sciences is a long-established healthcare investment firm focused principally on biopharmaceuticals and related life-sciences opportunities. It supports companies through formation, early development, clinical progress, and later private financing.

The firm combines scientific and clinical judgment with operating and capital-markets experience. Such continuity is valuable where investors must determine whether development milestones, syndicate composition, and financing reserves are sufficient to carry a program through volatile market conditions.

Frazier fits Tier II because its healthcare specialization, long institutional history, company-development experience, and presence across major US life-sciences hubs make it an established specialist platform.

MPM BioImpact

• Headquarters: Boston, United States
• Founded: 1997

MPM BioImpact builds and invests in biotechnology companies across private and public markets, with a principal focus on developing medicines. Its team combines scientific research, drug development, company creation, clinical strategy, intellectual property, and commercialization experience.

The firm remains active in internal company formation and in cross-border therapeutic development. Its platform can support companies from scientific concept through later clinical and public-market stages, providing continuity across a capital-intensive development cycle.

MPM BioImpact fits Tier II because its long biotech history, venture-building capability, therapeutic specialization, and continued organizational activity give it substantial authority, even though its investment platform extends beyond private venture alone.

Omega Funds

• Headquarters: Boston / Geneva, United States / Switzerland
• Founded: 2004

Omega Funds is a global healthcare investment firm focused on creating and financing life-sciences companies developing medicines for significant medical needs. It invests from company creation and early venture through later private rounds, direct secondaries, and selected public financings.

Its stage-flexible model allows the firm to follow scientific conviction rather than one narrow financing category. Omega’s presence in Boston and Geneva supports investment and syndication across North American and European biotechnology ecosystems.

Omega fits Tier II because its long specialist history, global reach, current fund platform, company-creation activity, and ability to provide several forms of healthcare capital establish it as a major institutional participant.

RA Capital Management

• Headquarters: Boston / San Francisco / New York, United States
• Founded: 2002

RA Capital Management is a full-lifecycle healthcare and life-sciences investment platform spanning company creation, venture financing, later private rounds, structured capital, and public markets. Its internal scientific research and company-building capabilities support evidence-based investment across therapeutics and related healthcare innovation.

The firm can originate companies, recruit teams, define development evidence, and continue financing as programs move toward clinical and public-market milestones. Its integrated model gives founders access to specialist research, operational resources, and capital across unusually broad stages.

RA Capital fits Tier II because its private-company franchise is substantial rather than incidental. Its scientific depth, scale, venture-creation infrastructure, and continuity from formation to public markets make it one of the most important additions to the expanded ranking.

Sofinnova Partners

• Headquarters: Paris / London / Milan, France / United Kingdom / Italy
• Founded: 1972

Sofinnova Partners is one of Europe’s longest-standing life-sciences venture firms. Its strategies cover biotechnology, therapeutics, medtech, industrial biotechnology, and related areas in which scientific development and company building are central to value creation.

The firm’s longevity provides experience across clinical, regulatory, financing, and exit cycles. Its European network also helps connect regional science with international management, pharmaceutical partners, specialist investors, and commercialization markets.

Sofinnova fits Tier II because its specialist heritage, institutional continuity, strategy breadth, and importance to the European life-sciences ecosystem make it a leading established healthcare venture firm.

---

Tier III — Specialist Healthcare & BioTech Venture Capital Firms

(Alphabetical order)

Advent Life Sciences

• Headquarters: London, United Kingdom
• Founded: 2006

Advent Life Sciences is a specialist investor and company builder focused on early-stage biotechnology and medical innovation. Its team works with founders on scientific and clinical strategy, operating plans, management development, syndication, and financing.

The firm’s approach is particularly relevant where a company must define the experiments and milestones that convert promising science into an investable therapeutic or product-development plan.

Advent fits Tier III because it is smaller than the major multi-office platforms, but its specialist team, UK ecosystem position, company-building orientation, and continued active identity make it a credible inclusion.

Brandon Capital

• Headquarters: Melbourne, Australia
• Founded: 2007

Brandon Capital is a life-sciences venture firm that develops biomedical discoveries from Australia, New Zealand, and connected international research ecosystems. It works with scientists, research institutions, and entrepreneurs to translate discoveries into therapeutics, medical technologies, and institutional companies.

The firm provides an important bridge from strong regional science and clinical networks into global financing, management, pharmaceutical, and commercialization channels.

Brandon fits Tier III because its geographic concentration limits its scale relative to the leading platforms, but its regional authority, specialist focus, and role in biomedical commercialization make it an important global category participant.

Define Ventures

• Headquarters: San Francisco, United States
• Founded: 2019

Define Ventures is an early-stage firm focused on health technology and the modernization of healthcare. It invests in software, data, care-delivery, payer, provider, consumer-health, and clinical platforms rather than concentrating on drug development.

Its team combines venture experience with healthcare operating knowledge and relationships across health systems, insurers, employers, and technology companies. That network can help founders refine market positioning, recruit leaders, build strategic partnerships, and secure follow-on capital.

Define fits Tier III because it is younger than the long-established life-sciences firms, but its focused healthtech mandate, institutional fund scale, operating expertise, and strong communications platform make it one of the category’s more relevant emerging specialists.

Epidarex Capital

• Headquarters: Bethesda / Edinburgh, United States / United Kingdom
• Founded: 2010

Epidarex Capital is a transatlantic venture firm focused on early-stage life sciences and health technology, particularly in research ecosystems that have strong science but less mature local venture infrastructure.

The firm works with universities, scientific founders, and regional innovation networks to form companies, establish early development plans, recruit management, and connect opportunities with wider institutional syndicates.

Epidarex fits Tier III because its platform is smaller than the leading transatlantic funds. Its focus on under-ventured research hubs and early scientific company formation nevertheless gives it a distinctive and defensible role.

Flare Capital Partners

• Headquarters: Boston, United States
• Founded: 2013

Flare Capital Partners is a dedicated healthtech venture firm investing in software, data, AI, infrastructure, and services that transform healthcare operations and delivery. Its portfolio addresses providers, payers, employers, clinical workflows, patient engagement, and related markets.

The firm’s strategic network connects founders with senior healthcare executives and prospective enterprise buyers. This is valuable in healthtech, where distribution, implementation, integration, and measurable return on investment often matter as much as the underlying software.

Flare fits Tier III because it is focused on healthcare technology rather than the full scientific and clinical-development spectrum. Its institutional platform, buyer network, and specialist authority make it an important counterweight to the ranking’s biotech concentration.

HealthQuest Capital

• Headquarters: San Francisco Bay Area, United States
• Founded: 2012

HealthQuest Capital invests in commercial-stage healthcare innovation across medical devices, diagnostics, digital health, healthcare services, and related technologies. It focuses on products and business models that can improve outcomes, efficiency, access, or cost within healthcare systems.

The firm is especially relevant where companies have moved beyond initial technical validation and need support with adoption, reimbursement, channel development, market expansion, and growth financing.

HealthQuest fits Tier III because its orientation is later and more commercially focused than that of biotech venture creators. Its category breadth and practical healthcare-market expertise strengthen the ranking’s coverage of medtech and delivery innovation.

Jeito

• Headquarters: Paris, France
• Founded: 2018

Jeito is an independent biopharma investment firm focused principally on clinical-stage companies developing therapies for severe diseases and unmet medical needs. Its multidisciplinary team spans drug development, regulation, intellectual property, manufacturing, commercial strategy, and market access.

The firm’s institutional position strengthened materially in 2026 with the closing of Jeito II above €1 billion. That capital allows it to provide substantial financing through successive clinical-development milestones and to support European companies with global ambitions.

Jeito fits Tier III because its history remains short relative to the established Tier II firms and its emphasis is later-stage biopharma rather than broad venture formation. Its scale, specialist team, independence, and recent momentum make it one of the strongest new inclusions.

Lightstone Ventures

• Headquarters: Portola Valley / Boston / Dublin, United States / Ireland
• Founded: 2012

Lightstone Ventures is a life-sciences firm focused on biotechnology and medical technology. It backs founders developing therapeutics, devices, and other medical products, often combining investment with hands-on company-building and operating support.

Its team brings experience across drug development, medtech formation, clinical affairs, reimbursement, commercialization, and venture-backed exits. The firm’s US and Irish presence also supports cross-border sourcing and syndication.

Lightstone fits Tier III because it is more concentrated than the larger global healthcare platforms. Its balanced biotech and medtech mandate, company-building orientation, and experienced operating network provide clear category relevance.

Medicxi

• Headquarters: London / Geneva, United Kingdom / Switzerland
• Founded: 2016

Medicxi is a European life-sciences investment firm formed by the former Index Ventures life-sciences team. It focuses on drug discovery and therapeutics, using structures designed to concentrate capital and management attention on clear development hypotheses and medical needs.

The firm’s network connects European scientific opportunities with experienced drug developers, pharmaceutical companies, and international capital. It invests through a current independent fund platform while continuing to manage the earlier Index life-sciences portfolio.

Medicxi fits Tier III because the standalone institution is younger and more narrowly therapeutic than the largest European platforms. Its team history, specialist model, and current fund activity give it substantial authority.

RiverVest Venture Partners

• Headquarters: St. Louis / San Diego / Cleveland, United States
• Founded: 2000

RiverVest Venture Partners is a life-sciences venture firm focused on biopharmaceutical and medical-device companies addressing significant medical needs. It supports product-oriented businesses in which clinical evidence, regulatory milestones, and a clear development pathway are central to value creation.

The firm provides specialist company-building and venture experience outside the largest coastal investment centers while maintaining relationships across national biotech, medtech, and institutional financing networks.

RiverVest fits Tier III because its scale and geographic footprint are narrower than those of the leading platforms. Its long operating history, product-development orientation, and clear healthcare identity justify continued inclusion.

Santé Ventures

• Headquarters: Austin, United States
• Founded: 2006

Santé Ventures is a healthcare and life-sciences investment firm backing companies across biotechnology, medical devices, diagnostics, health technology, and care delivery. Its mandate allows it to evaluate innovation across both scientific products and healthcare business models.

The firm’s team combines investment, clinical, operating, and entrepreneurial experience. That breadth is useful where companies must coordinate technical development with regulation, reimbursement, provider adoption, and commercial execution.

Santé fits Tier III because its institutional scale is below that of the leading national healthcare platforms, but its long specialist history, broad healthcare coverage, and active US market presence make it a credible inclusion.

SV Health Investors

• Headquarters: Boston / London, United States / United Kingdom
• Founded: 1993

SV Health Investors is a transatlantic healthcare investment platform with specialist teams across biotechnology, dementia, medtech, and healthcare growth. Its long history and diversified fund structure allow it to invest across development stages while retaining a clear healthcare identity.

The platform combines venture financing with company-building, clinical, operating, and growth expertise. Its Boston and London teams connect US and UK scientific and healthcare markets and support cross-border development and syndication.

SV Health Investors fits Tier III because parts of its platform extend into growth equity and buyouts rather than venture alone. Its healthcare specialization, long continuity, active biotech and medtech franchises, and substantial institutional base make exclusion difficult to justify.

venBio

• Headquarters: San Francisco, United States
• Founded: 2011

venBio is a life-sciences investment firm focused on therapeutics and technologies addressing important unmet medical needs. Its team emphasizes scientific differentiation, clinical relevance, development strategy, and the construction of companies around credible product opportunities.

The firm’s concentrated specialist model allows close engagement with management teams and clinical programs. It is particularly well suited to a selective environment in which biological plausibility and development discipline carry more weight than broad platform narratives.

venBio fits Tier III because it is narrower in institutional scale and strategy breadth than the firms placed in Tier II. Its scientific focus and established therapeutics franchise nevertheless make it a strong specialist inclusion.

Vida Ventures

• Headquarters: Boston / San Francisco, United States
• Founded: 2017

Vida Ventures is a life-sciences investment firm founded by scientists, physicians, entrepreneurs, and investors. It builds and finances biomedical companies across stages, with its principal focus on therapeutics and the translation of scientific innovation into medicines.

Its flexible mandate supports de novo company formation as well as investment in established private businesses. The team’s scientific, clinical, and operating experience helps companies evaluate development programs, recruit leadership, and plan successive financing milestones.

Vida fits Tier III because it is younger than the long-established Tier II institutions. Its specialist team, bicoastal presence, meaningful capital base, and clear biomedical identity give it stronger substance than many similarly aged healthcare funds.

Wellington Partners Life Sciences

• Headquarters: Munich, Germany
• Founded: 1998

Wellington Partners Life Sciences is a European venture firm investing in early- and growth-stage companies across therapeutics, medical devices, diagnostics, digital health, and industrial biotechnology. Its platform is rooted in Germany but invests across wider European markets.

The firm helps scientific and medical entrepreneurs move from technical development toward international financing, clinical validation, regulatory progress, and commercial scale. Its cross-subsector portfolio gives it experience across several healthcare development models.

Wellington fits Tier III because its current fund scale is smaller than that of the largest European specialists. Its long operating history, DACH position, active portfolio, and broad life-sciences mandate make it an important regional inclusion.

---

Remarks

Healthcare and biotech venture capital is not one homogeneous strategy. The selected firms include scientific venture creators, early-stage therapeutics investors, multi-stage healthcare managers, clinical-development specialists, medtech funds, diagnostics investors, healthtech platforms, and cross-border institutions connecting research ecosystems with global capital.

The 2026 environment rewards specialization and financing discipline at the same time. Aggregate capital is recovering, but deal concentration remains high and development standards are demanding. Biotechnology companies must show biological rationale, translational evidence, differentiated development plans, and sufficient financing durability. Medtech and healthtech companies must demonstrate regulatory feasibility, adoption, reimbursement or customer economics, workflow integration, and measurable value.

Artificial intelligence is increasing opportunity across drug discovery, diagnostics, clinical development, medical imaging, provider operations, and patient care. It also raises the risk of superficial differentiation. The strongest healthcare investors can determine whether AI improves scientific evidence or operational performance, whether the relevant data and workflows are defensible, and whether clinical users and enterprise buyers will adopt the product.

The leading firms combine capital with scientific, clinical, and commercial infrastructure. They can help founders secure intellectual property, recruit specialized executives, design development programs, access investigators and health systems, build international syndicates, form pharmaceutical or strategic partnerships, and raise follow-on capital through long and uncertain development cycles.

Tier classification reflects relative institutional positioning within the healthcare and biotech venture-capital segment. It does not represent investment performance, fund returns, the scientific validity or clinical prospects of any portfolio company, regulatory approval, or an endorsement of any fund, manager, security, therapy, medical product, or investment strategy.

---

Recognition

Inclusion in the Top 30 Healthcare & BioTech Venture Capital 2026 ranking is an editorial determination of The Economy Rankings and is independent of licensing, advertising, sponsorship, or other commercial participation.

Ranked organizations may factually refer to their inclusion in the ranking in their own communications. When describing the result, firms should accurately reflect the tier structure and methodology used in the published ranking.

How the ranking should be interpreted

• Tier I represents the Top 5 firms, and the published order within Tier I reflects the ranking order.
• Tier II represents firms ranked within the Top 15, following Tier I. Firms within Tier II are displayed alphabetically; their displayed order should therefore not be interpreted as an individual numerical ranking.
• Tier III represents firms ranked within the Top 30, following Tiers I and II. Firms within Tier III are also displayed alphabetically, and their displayed order should not be interpreted as an individual numerical ranking.
• A firm's tier, rather than its alphabetical position within Tier II or Tier III, should therefore be used when describing its standing.

Referencing the ranking

Depending on the firm's published tier, appropriate factual descriptions may include:

• Tier I: “Ranked Tier I” or “Ranked among the Top 5”
• Tier II: “Ranked Tier II” or “Ranked among the Top 15”
• Tier III: “Ranked Tier III” or “Ranked among the Top 30”

Firms should not describe an alphabetical position within Tier II or Tier III as a specific numerical rank.

Use of The Economy Rankings recognition materials

Editorial inclusion in a ranking does NOT by itself grant permission to use The Economy Rankings badges, seals, logos, official recognition graphics, licensed quotations, or other proprietary recognition materials.

Organizations wishing to use official The Economy Rankings recognition materials in corporate websites, marketing materials, investor communications, client presentations, social media, press releases, or other external communications should refer to the applicable licensing terms and usage policies:

• The Economy Rankings License Structure — available licence levels and permitted recognition uses
  Rankings License Structure | The Economy
• The Economy Rankings License Policy — licensing conditions governing use of The Economy Rankings recognition, marks, and related materials
  The Economy Rankings License Policy | The Economy
• Recognition Use Guide — guidance on permitted wording, presentation, attribution, and use of ranking recognition
  Recognition Use Guide | The Economy

Ranking inclusion remains editorially independent regardless of whether an organization purchases or holds a recognition-materials licence.

Recognized institutions may reference the designation in:

• corporate websites
• investor communications
• marketing materials
• client presentations

Licensing inquiries:
[email protected]